Dr Sara Hurvitz talks to ecancer for the ESMO 2021 meeting about the interim results from the phase II coopERA BC study which looked at giredestrant plus palbociclib vs anastrozole plus palbociclib for post-menopausal, oestrogen receptor-positive, HER2-negative, untreated early breast cancer.

She explains that the trial evaluates these treatments by comparing the change in proliferation of the tumour, as measured by marker Ki-67.

Dr Hurvitz reports that the relative Ki-67 reduction was greater, with more tumours exhibiting complete cell cycle arrest, in the giredestrant arm than in the anastrozole arm.